<p>小野製藥公司（OTCMKTS:OPHLF - 獲取免費報告）在週五上漲了 14.5%。該股票最高交易價格為$18.67，最後交易價格為$18.67。在午盤交易中，約有 300 股被交易，較平均每日交易量 433 股下降了 31%。該股票之前的收盤價為$16.30。</p>
<p>獲取 <strong>小野製藥</strong> 的提醒：</p>
<h2>小野製藥股票表現</h2>
<p>該公司的 50 日簡單移動平均線為$14.02，200 日簡單移動平均線為$12.43。公司的流動比率為 3.02，速動比率為 2.56，債務與股本比率為 0.10。該股票的市值為$87.7 億，市盈率為 20.98，貝塔值為 0.25。</p>
<p>小野製藥（OTCMKTS:OPHLF - 獲取免費報告）最後一次公佈季度財報是在 2 月 2 日，星期一。公司報告該季度每股收益為$0.40，超出市場共識預期的$0.29，超出幅度為$0.11。該季度公司的收入為$8.927 億，而分析師預期為$7.2758 億。小野製藥的股本回報率為 7.76%，淨利潤率為 12.29%。</p>
<h2>小野製藥公司簡介</h2>
<p>（獲取免費報告）</p>
<p>小野製藥株式會社成立於 1717 年，總部位於日本大阪，是一家以研究為基礎的製藥公司，專注於創新療法的發現、開發和營銷。小野製藥起源於傳統藥房，現已發展成為一家全球生物製藥實體，致力於在多個治療領域提供新的治療選擇，包括腫瘤學、免疫學、心血管疾病和抗病毒疾病。該公司開展全面的研究項目，涵蓋從早期藥物發現到臨牀開發的各個階段。</p>
<p>小野製藥最知名的產品之一是免疫檢查點抑制劑 nivolumab，與百時美施貴寶合作以 Opdivo 的商標進行營銷。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票超過小野製藥</li>
<li>你的銀行賬户不再安全</li>
<li>Nvidia CEO 發出大膽的特斯拉呼籲</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在小野製藥嗎？</h2>
<p>在考慮小野製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而小野製藥並不在名單上。</p>
<p>雖然小野製藥目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

小野制藥(ADR)

4528

<p>小野製藥 (ADR)（OTCMKTS:OPHLF）股價上漲 14.5%，達到 18.67 美元，交易量為 300 股。該公司報告每股收益為 0.40 美元，超出預期，收入為 8.927 億美金。小野專注於創新療法，特別是在腫瘤學和免疫學領域，市值為 87.7 億美元。分析師目前對該股票的評級為持有，暗示可能有更好的投資選擇</p>

<p>Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) was up 14.5% on Friday . The stock traded as high as $18.67 and last traded at $18.67. Approximately 300 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 433 shares. The stock had previously closed at $16.30.</p>
<div class="lb-trans"><p>小野製藥公司（OTCMKTS:OPHLF - 獲取免費報告）在週五上漲了 14.5%。該股票最高交易價格為$18.67，最後交易價格為$18.67。在午盤交易中，約有 300 股被交易，較平均每日交易量 433 股下降了 31%。該股票之前的收盤價為$16.30。</p>
</div><p>Get <strong>Ono Pharmaceutical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>小野製藥</strong> 的提醒：</p>
</div><h2>Ono Pharmaceutical Stock Performance</h2>
<div class="lb-trans"><h2>小野製藥股票表現</h2>
</div><p>The firm has a fifty day simple moving average of $14.02 and a 200 day simple moving average of $12.43. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10. The stock has a market cap of $8.77 billion, a price-to-earnings ratio of 20.98 and a beta of 0.25.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為$14.02，200 日簡單移動平均線為$12.43。公司的流動比率為 3.02，速動比率為 2.56，債務與股本比率為 0.10。該股票的市值為$87.7 億，市盈率為 20.98，貝塔值為 0.25。</p>
</div><p>Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.11. The company had revenue of $892.70 million for the quarter, compared to analyst estimates of $727.58 million. Ono Pharmaceutical had a return on equity of 7.76% and a net margin of 12.29%.</p>
<div class="lb-trans"><p>小野製藥（OTCMKTS:OPHLF - 獲取免費報告）最後一次公佈季度財報是在 2 月 2 日，星期一。公司報告該季度每股收益為$0.40，超出市場共識預期的$0.29，超出幅度為$0.11。該季度公司的收入為$8.927 億，而分析師預期為$7.2758 億。小野製藥的股本回報率為 7.76%，淨利潤率為 12.29%。</p>
</div><h2>Ono Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>小野製藥公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.</p>
<div class="lb-trans"><p>小野製藥株式會社成立於 1717 年，總部位於日本大阪，是一家以研究為基礎的製藥公司，專注於創新療法的發現、開發和營銷。小野製藥起源於傳統藥房，現已發展成為一家全球生物製藥實體，致力於在多個治療領域提供新的治療選擇，包括腫瘤學、免疫學、心血管疾病和抗病毒疾病。該公司開展全面的研究項目，涵蓋從早期藥物發現到臨牀開發的各個階段。</p>
</div><p>One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.</p>
<div class="lb-trans"><p>小野製藥最知名的產品之一是免疫檢查點抑制劑 nivolumab，與百時美施貴寶合作以 Opdivo 的商標進行營銷。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Ono Pharmaceutical</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過小野製藥</li>
<li>你的銀行賬户不再安全</li>
<li>Nvidia CEO 發出大膽的特斯拉呼籲</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ono Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在小野製藥嗎？</h2>
</div><p>Before you consider Ono Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮小野製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ono Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而小野製藥並不在名單上。</p>
</div><p>While Ono Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然小野製藥目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

小野製藥 (ADR) (OTCMKTS:OPHLF) 股價上漲 14.5% - 是否值得購買？